Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 31, 2025

Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of hospital-acquired renal impairment in patients undergoing intervention. Limited clinical trials explore SGLT2 inhibitors' effects on CI-AKI. This study aimed to assess the short-term effect empagliflozin- an inhibitor- reducing CI-AKI incidence PCI regardless diabetes. research conducted double-blind randomized trial involving 121 referred Ghaem Hospital, Mashhad, Iran from 2022 2023. Participants were randomly assigned receive empagliflozin (10 mg daily) or placebo, starting one day before and continuing for two days post-procedure. Renal function parameters such as estimated glomerular filtration rate (eGFR), creatinine, cystatin C, urea evaluated. After intervention, users exhibited significant reduction mean C levels compared placebo across all age groups (< 50 years, 50–60 > 60 years). Patients older than showed improvements changes eGFR with empagliflozin. 45 < had increase group. Mean significantly reduced (> 60, 45–60, 45). There was no difference creatinine between groups. Empagliflozin notably decreases by improving C. These benefits observed various groups, particularly middle-aged elderly, those varying levels.

Language: Английский

---

Effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin and canagliflozin, on the musculoskeletal system in an experimental model of diabetes induced by high-fat diet and streptozotocin in rats

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117912 - 117912

Published: Feb. 16, 2025

Language: Английский

---

Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases

Physiological Research, Journal Year: 2024, Volume and Issue: Suppl 1, P. S377 - S387

Published: Aug. 22, 2024

A new class of antidiabetic drugs - gliflozins (inhibitors sodium glucose cotransporter-2; SGLT-2i) stimulate and excretion, thereby contributing to improved glycemic control, weight loss blood pressure reduction in diabetic patients. Large clinical trials patients with type 2 diabetes treated empagliflozin, canagliflozin or dapagliflozin have demonstrated their excellent efficacy improving many cardiovascular outcomes, including the death from diseases, non-fatal myocardial infarction stroke, hospitalization for heart failure. Moreover, beneficial effects SGLT-2i were also decrease proteinuria, which leads a lower risk progression end-stage renal disease thus delay initiation replacement therapy. Unexpectedly, cardioprotective renoprotective been not only but those without diabetes. Recently, much effort has focused on failure (either reduced preserved ejection fraction) liver disease. Experimental studies highlighted pleiotropic SGLT-2 inhibitors beyond natriuretic glycosuric effects, fibrosis, inflammation, reactive oxygen species, others. Our results experimental non-diabetic models hypertension, chronic kidney are partially consistent these findings. This raises question whether same mechanisms at work conditions, responsible under conditions. Are cardio-renal, metabolic, others? review will focus different pathophysiological namely disease, failure, evaluated rat diseases. Key words: inhibitor, rat.

Language: Английский

---

Glucose transporters and their energy homeostasis function in various organs

Vitamins and hormones, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 47

Published: Aug. 24, 2024

Language: Английский

---